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Abstract
Background: Whether androgen deprivation therapy (ADT) leads to stroke morbidity is still unclear because of
inconsistent evidence. We performed a systematic review and meta-analysis to evaluate if ADT used in men with
prostate cancer (PCa) is associated with stroke.
Methods and results: Medline, Embase and Cochrane Library databases up to September 30th 2014 were
systematically searched with no date or language restriction, and reports from potentially relevant journals were
complementally searched. Both randomized controlled trials and observational studies were included. Two reviewers
independently extracted data and assessed study quality. Six observational studies finally met inclusion criteria,
with 74,538 ADT users and 85,947 non-ADT users reporting stroke as an endpoint. Although no significant
association was observed in pooled estimates, the incidence of stroke in ADT users was 12 % higher than
control groups, (HR = 1.12, 95 % confidence interval [CI]: 0.95 to 1.32; P = 0.16). In subgroup-analyses of different
ADT types, stroke was found to be significantly associated with gonadotropin-releasing hormone (GnRH) alone (HR = 1.20,
95 % CI: 1.12 to 1.28; P < 0.001), GnRH plus oral antiandrogen (AA) (HR = 1.23, 95 % CI: 1.13 to 1.34; P < 0.001) and
orchiectomy (HR = 1.37, 95 % CI: 1.33 to 1. 46; P = 0.001), but not with AA alone (HR = 1.06, 95 % CI: 0.71 to 1.57; P = 0.78).
Conclusions: GnRH alone, GnRH plus AA and orchiectomy is significantly associated with stroke in patients with PCa.
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Background
Prostate cancer (PCa) is the most prevalent malignancy
and remains a major healthcare problem in men in the
United States [1]. Because the development and growth
of PCa cells depends on androgens [2, 3], Androgen
deprivation therapy (ADT) undoubtedly plays an import-
ant role to treat PCa, and recently, approximately 40 %
of men diagnosed with PCa within 6 months have been
treated with ADT in the US [4].
ADT is a palliative therapy, including different types of
treatments such as gonadotropin-releasing hormone
(GnRH), oral antiandrogen (AA), orchiectomy, and two
or more types above combined. Although ADT is
increasingly used as a treatment for PCa, this effect on
prolonging life expectancy is unclear or even negative in
several clinical studies [5, 6]. In our previous study [7],
we found that ADT was positively associated with car-
diovascular disease. Because both cardiovascular and
cerebrovascular diseases share many common risk
factors including atherosclerosis, dyslipidemia, visceral
obesity, arterial endothelial dysfunction, and hyperten-
sion [8–12], ADT may also be associated with stroke.
Additionally, one population-based cohort study [13]
demonstrated that, GnRH agonists could significantly in-
crease the risk of stroke (adjusted rate ratio [RR], 1.18;
95 % confidence interval [CI], 1.00–1.39). However, con-
flicting results were also reported. In a nation-wide
population-based cohort study [14], authors found that
ADT was associated with decreased stroke risk (adjusted
hazard ratio [HR], 0.88; P = 0.001). Therefore, there is
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still no consensus regarding that ADT is associated with
stroke.
Based on the controversy of this clinical issue, we per-
formed a meta-analysis and systematic review to investi-
gate whether ADT is associated with stroke in patients
with PCa.
Methods
Search strategy and study selection
We systematically searched Medline, Embase and
Cochrane Library databases up to September 30th 2014,
with all possible combinations of the keywords as follows:
prostate cancer or prostate tumor or prostate carcinoma,
androgen deprivation or androgen suppression or endo-
crine treatment or ADT or AST; and stroke or cerebrovas-
cular or transient ischemic attack or hemiplegia or TIA or
cardiovascular (Additional file 1: Methods S1). No lan-
guage, date, or other restrictions was used. Publications
from potentially relevant journals were complementally
searched.
Studies were included if they fulfilled the following in-
clusion criteria: 1) Patients diagnosed with PCa only; 2)
Intervention groups must include ADT (either mono-
therapy or combination therapy); 3) Treatments in con-
trol groups were non-ADT (e.g. radical prostatectomy,
radiotherapy, active surveillance.); 4) Studies must have
the data of risk estimates with 95 % CIs; 5) Studies must
report comparative data. If more than one study were
identified from the same population, we extracted data
from all available informations, rather than just a single
publication.
Data extraction and quality assessment
Two reviewers (Meng & Zhu) independently extracted
the data from eligible and potentially relevant publica-
tions, with differences resolved by the third reviewer
(Niu) as necessary. General characteristics of each in-
cluded publication were recorded: first author’s name,
year of publication, medical center, study design, sample
size, population characteristics, follow-up period, inter-
ventions, definition of stroke morbidity, HRs and corre-
sponding 95 % CIs of estimates in each comparisons.
Definition of stroke was according to what descripted in
each included publication. Our meta-analysis involved
different types of ADT including AA, GnRH agonists,
orchiectomy, and two or more types above combined.
Study qualities of the selected trials were assessed by
the Jadad score [15]. Trails were considered to be of
high quality if they achieved more than 4 scores.
Newcastle-Ottawa quality assessment scale (NOS) [16]
was used to assess the observational studies. Studies
with more than 6 scores were considered high-quality.
Two authors (Zhu & Meng) respectively addressed the
assessments and discussed the discrepancies until
agreement reached. Level of evidence (LOE) of all eli-
gible publications were evaluated using the classifica-
tions of Phillips et al’s, [17].
Subgroups analyses
In order to minimize the influence of concomitant treat-
ments (e.g. radiotherapy and prostatectomy), subgroup
analysis of ADT monotherapy vs watchful waiting or
active surveillance (WW/AS) for stroke morbidity was
carried out. ADT monotherapy was defined as a single
therapeutic that in addition to ADT, no other previous
therapy was used in intervention group. Considering the
significance of existing heterogeneity in overall-analysis,
additional subgroup-analyses for various types of ADT
(e.g. GnRH, AA, GnRH +AA and Orchiectomy) vs non-
ADT were also performed.
Statistical analysis
Using the same methods as in our previous study [18],
weighted HRs and 95 % CIs were estimate to compare
all of these dichotomous variables. Different methods
were employed to calculate the HRs on the basis of the
data provided in the studies. When studies compared
more than one types of ADT with the same control
group severally (for example, GnRH vs Control, Orchi-
ectomy vs Control), random effects meta-analyses were
used to combine these results together as necessary.
Statistical heterogeneity among studies was evaluated
with the Cochrane’s Q statistic [19]. In addition, incon-
sistency was quantified by I2 statistic (100 % × [(Q-df )/
Q]), different I2 values (25, 50, and 75 %) denote differ-
ent levels (low, medium, and high levels) of heterogen-
eity [20]. Using the Der-Simonian and Laird method, we
chose random-effects models throughout this analysis
no matter whether heterogeneity existed or not.
We used Begg adjusted rank correlation test and Egger
linear regression test to evaluate publication bias. All
meta-analyses were conducted with Review Manage
(version 5.3; The Cochrane Collaboration, Oxford) and
STATA software (version 11.0; College Station, Texas).
Two-tailed P < 0.05 indicated significant difference
statistically.
Results
Based on the titles, abstracts, and full text screening, we
finally identified five cohort studies [14, 21–24] and one
nested case–control study [13] that met the inclusion
criteria. All articles included were published in English.
Details of reasons for exclusion of articles through full
text screening are shown in Additional file 1: Table S1.
Figure 1 shows the literature search and study selection
process of our meta-analysis.
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Study characteristics and study quality
HRs and 95 % CIs were directly given in two publications
[14, 21], and four studies [13, 14, 23, 24] respectively com-
pared different types of ADT with control groups. All of
these observational studies were of high LOE (2a). Details
of the eligible studies were summarized in Table 1.
According to the assessment of NOS for observational
studies, all eligible studies were high-quality with scores
more than seven stars (Additional file 1: Table S2).
Meta-analysis results
Six studies [13, 14, 21, 23–25] involving 160,485 partici-
pants were identified for inclusion criteria. Figure 2a
showed the impact of ADT vs non-ADT on the end
point of fatal or non-fatal stroke morbidity. 5578 (7.4 %)
stroke events occurred among 74,538 ADT users compared
with 5134 events (5.7 %) within control participants. Pooled
HR showed that the incidence of stroke morbidity in ADT
group was 12 % higher than non-ADT users, although sta-
tistically significant difference was not observed (HR = 1.12;
95 % CI, 0.95–1.32; P = 0.16). As to subgroup-analyses of
different types of ADT, four studies [13, 23–25] were identi-
fied: three studies [13, 23, 24] respectively compared AA
alone, GnRH alone and GnRH plus AA with control
groups, four studies [13, 23–25] were available for the
subgroup-analyses of orchiectomy vs non-ADT. Figure 3
showed the subgroup analyses for the effect of different
types of ADT vs control on stroke events. Stroke was sig-
nificantly associated with GnRH alone (HR = 1.20; 95 % CI
1.12–1.28; P < 0.001), GnRH plus AA (HR= 1.23; 95 % CI
1.13-1.34; P < 0.001), and orchiectomy (HR= 1.37; 95 % CI
1.33–1.64; P = 0.001), but not with AA alone (HR = 1.06;
95 % CI 0.71–1.57; P = 0.78). Details of meta-analyses for
each type of ADT were shown in Additional file 1: Figure
S1. Additionally, two studies [23, 24] with 81,402 pa-
tients were included for subgroup analysis of ADT
monotherapy vs WW/AS. 6150 stroke events were re-
corded, containing 3317 events from ADT users (8.2 %)
and 2349 from WW/AS groups (5.5 %). Pooled result re-
vealed that ADT monotherapy could significantly increase
the risk of stroke, with a higher incidence of 16 % than
WW/AS (HR = 1.16, 95%CI: 1.03–1.31, P = 0.01; Fig. 2b).
Discussion
Although the occurrence of stroke in men undergoing
ADT with PCa has been an emerging problem over re-
cent years, the relationship between ADT and stroke
morbidity is still unclear. This meta-analysis including
five population-based observational studies showed that
ADT has a tendency to increase the risk of stroke. Evi-
dence was directly proved by Azoulay et al. [13], show-
ing that ADT could significantly increase the risk of
stroke over a median follow-up of 3.9 years in men with
newly diagnosed PCa (HR = 1.34, P = 0.0001). Another
cohort study [24] involving 29,443 ADT users, and
19,527 with surveillance showed the standardized mor-
tality ratios of stroke was 1.17.
ADT is considered to be effective when serum testos-
terone is declined to the recommended levels of 50 ng/
dl, according to the 2012 NCCN (National Comprehen-
sive Cancer Network) guidelines [26]. However, How-
ever, as reported in our previous study [7], low level of
serum testosterone is likely related to many stroke risk
factors including high triglyceride and low-density lipo-
protein cholesterol levels, endothelial dysfunction and
proinflammatory factors [12, 27–29]. In addition, previ-
ous studies [11, 30] showed that testosterone deficiency
was significantly associated with hypertension, high body
mass index, hypercoagulable states, and hyperfibrinogen-
emia [31]. All of these adverse effects may put patients
at a high risk of stroke.
Out of the six studies we analyzed, only one [14] did
not show the positive relationship between ADT and
stroke (HR = 0.88; P = 0.001). This inconsistency was
likely due to the contamination bias caused by radical
prostatectomy. To reduce this bias, a sensitivity analysis
was performed comparing ADT monotherapy with
WW/AS. When ADT users undergoing other treatments
were excluded, more significantly increased risk of
Fig. 1 Flow Diagram of Search Strategy and Study Selection
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Cohort, 2a Danish Cancer
Registry (2002–2010)
Ischemic Stroke/TIA
(ICD-8 codes 433, 434.09/99,
436.01/436.90, ICD-10 codes
DI63.x, DI64.x)
GnRH/AA non-ADT 9204 20,307 71 3.3
(1.8 to 5.2)




Cohort, 2a NPCR of Sweden
(1997–2007)
Stroke (ICD-10: 160–164, G45) GnRH
agonist
RP 9066 26,432 ≤65: 19,153 3.8 4.4 1.21(1.11,1.32)b 1.16 (1.01, 1.32)d
AA 3391 4 0.88(0.76,1.00)b
GnRH + AA WW/AS 11,646 19,527 66 to 74:
27,737
3.3 4.7 1.25(1.15,1.35)b
Orchiectomy 5340 ≥75: 13,110 3.1 1.30(1.18,1.44)b
Other types 1199 - -
Alibhai et al.
[14] 2009
Cohort, 2a ICES (1995–2005) Stroke (ICD-9-CM codes
430–438)
ADT non-ADT 19,079/19,079 75 ± 6.3 6.47 0.88(0.81,0.96)c
Keating et al.
[23] 2010




(ICD-9 codes 433.XX −435.XX)
GnRH
agonist
WW/AS 14,037 22,846 66.9 ± 8.6 2.6 1.18(1.02,1.36)c 1.18 (0.91, 1.51)d
AA 1229 0.89(0.46,1.73)c




Cohort, 2a Queen Mary Hospital,
Hong Kong (1998–2011)





GPRD (1988–2008) Stroke/TIA (NA) GnRH
agonist
non-ADT 3274 3960 72.3 ± 3.9 3.9 1.18(1.00,1.39)c 1.34 (1.15, 1.55)d
AA 457 1.47(1.08,2.01)c
GnRH + AA 481 1.26(0.93,1.72)c
Orchiectomy 295 1.77(1.25,2.51)c
Other types 142 1.42(0.84,2.39)c
Abbreviations: LOE level of evidence, ADT androgen deprivation therapy, GnRH gonadotropin-releasing hormone (leuteinizing hormone releasing hormone, LHRH), AA oral antiandrogens, RP radical prostatectomy/cura-




cHR was directly given in the publication












stroke was observed in ADT monotherapy users
(Fig. 2b).
There may be bias in the results due to different types
of ADT that were used in some studies [13, 23–25].
Therefore, we carried out subgroup analyses stratified by
different types of ADT in order to reduce this
heterogeneity, and showed that stroke morbidity was sig-
nificantly associated with GnRH alone, GnRH plus AA,
and prostatectomy. The US Food and Drug Administra-
tion announced a safety warning that GnRH agonists
could increase the risk of stroke in men receiving these
drugs for treating PCa [1]. As previously reported [32],
Fig. 2 a. HRs of Stroke Related to ADT. b. HRs of Stroke Related to ADT Monotherapy vs WW/AS
Fig. 3 HRs of Subgroup Analyses for Stroke Related to Different Types of ADT
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GnRH agonist may cause the development of metabolic
syndrome, which in turn could accelerate the athero-
sclerotic process and then lead to increased stroke mor-
bidity. One included cohort study [23] investigating the
relationship between GnRH and stroke over a median
follow-up of 2.6 years, concluded that GnRH was signifi-
cantly associated with stroke morbidity (adjusted HR =
1.18, P = 0.03). All of these listed above was in accord-
ance with our findings.
This meta-analysis and systematic review has several
strengths. First, the included studies were all large-scale
observational studies with long term of follow-up. Sec-
ond, if the HRs were not available in eligible studies, all
the data which could be used to calculate these were ad-
justed for the durations of follow-up. Finally, funnel
plots showed balance in our assessment of publication
bias. Begg’s and Egger’s tests also indicated that no sig-
nificant publication bias existed (Table 2). Additionally,
there was no obvious publication bias as shown in Add-
itional file 1: Figure S2, since points are distributed
around the verticals. Therefore, the findings in this
meta-analysis can be considered credible.
However, we acknowledge that several limitations
should be taken into consideration with the results
found in this meta-analysis. First, all eligible reports
were retrospective observational studies, which may
introduce recall limitation, so the integrity of records
may weaken the reliability of the results to some extent.
Second, selection bias may have influenced our results.
To minimize this bias, we carried out a predesigned
search strategy with independent selection, and data was
extracted by two reviewers. Third, incomplete data in
some included publications [24, 25] may have influenced
the overall result. As described in detail in our previous
study [7], we have tried to minimize this limitation as
much as possible. Furthermore, the stroke definition (is-
chemic, hemorrhagic, or TIA) was not specified in some
studies [13, 14, 24], introducing potential bias in stroke
incidence estimate. However, most of events in these eli-
gible studies were defined as ischemic events, and this
bias is possibly minimized because these overall stroke
rates were similar to the study [23] only including
ischemic events as the endpoint. Finally, the certain
characteristics of patients that may contribute to stroke
were different in each included study, which might con-
found the presented results. Therefore, adjusted data
were extracted when available to minimize the bias.
Conclusion
In conclusion, there is a tendency that ADT could in-
crease the risk of stroke. Significant association of ADT
monotherapy with stroke was observed after removing
patients with prostatectomy and radiotherapy. Addition-
ally, GnRH, GnRH plus AA, and orchiectomy can sig-
nificantly result in stroke. These findings may help
clinicians be aware of the potential risks of ADT and en-
sure clinical management when prescribing this treat-
ment. Additional studies should also focus on the
different definitions of stroke since they require different
approaches to treatment.
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Table 2 Pooled Results and Publication Bias for All Comparisons
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test (P)
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